Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the efficacy of afatinib in NSCLC harbouring
EGFR PACC mutation subtype. The main question it aims to answer is:
Afatinib is active in patients with advanced NSCLC harbouring EGFR PACC mutation subtype.
Participants will undergo screening, follow by treatment if eligible for study participation
and then enter follow up phase after study medication has stopped. Patients will take
afatinib 40mg daily continuously, until the development of progressive disease or meeting
discontinuation criteria. A treatment cycle is defined as 28 days.